Assenagon Asset Management’s Solid Biosciences SLDB Stock Holding History

Assenagon Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,726	Closed	-$45K	–	1549
2021 Q4	$45K	Buy	+1,726	New	+$52.8K	﹤0.01%	1407
2021 Q3	–	Sell	-2,840	Closed	-$156K	–	1418
2021 Q2	$156K	Buy	+2,840	New	+$188K	﹤0.01%	1160
2019 Q3	–	Sell	-20,002	Closed	-$1.73M	–	1055
2019 Q2	$1.73M	Buy	+20,002	New	+$2.18M	0.01%	567

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Assenagon Asset Management's SLDB Position: Q1 2022 in Review

Assenagon Asset Management sold out of Solid Biosciences (SLDB) in Q1 2022, closing a stake of 1,726 shares — an estimated $45K sold.

Assenagon Asset Management first reported a position in SLDB in Q2 2019 and held it in 3 quarters. The position peaked at $1.73M in Q2 2019. 77 funds tracked by Wall St. Rank hold SLDB as of Q1 2022.

Assenagon Asset Management reported no remaining Solid Biosciences position as of Q1 2022 after selling out during the quarter.
Assenagon Asset Management sold 1,726 Solid Biosciences shares in Q1 2022, an estimated $45K.
Assenagon Asset Management first reported a position in Solid Biosciences in Q2 2019 and held it in 3 quarters.
Assenagon Asset Management's Solid Biosciences position peaked at $1.73M in Q2 2019.
77 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2022.

Based on Assenagon Asset Management's 13F filing for Q1 2022, filed 25 Apr 2022.